Abstract
BackgroundThis paper aims to compare the efficacy and safety of recombinant human endostatin combined with chemotherapy in patients with squamous cell lung cancer (SqCLC).MethodsWe searched the Cochrane Library, PubMed, Embase, CNKI, Wanfang database, Metstr, VIP, and others and manually searched books and magazines until 2019 for articles about the efficacy and safety of recombinant human endostatin combined with chemotherapy in patients with SqCLC. A second search was conducted on the review literature. According to the criteria of the literature screen, the relevant randomized controlled trials (RCTs) and nonrandomized controlled trials (non-RCTs) of recombinant human endostatin combined with chemotherapy and chemotherapy alone in the treatment of SqCLC were included. After the data were extracted and analyzed, RevMan 5.3 software was used for meta-analysis for the outcome indicators. Then, heterogeneity tests and sensitivity analyses were carried out, and the publication bias of this study was tested in Stata 13.0 software. Six RCTs and eight non-RCTs were included. In total, 821 patients with SqCLC were included.ResultsThe response rate (RR) was 2.12 (95% CI: 1.57–2.85, p < 0.00001). The disease control rate (DCR) was 2.38 (95% CI: 1.70–3.32, p < 0.00001). The difference between the two groups was statistically significant. Regarding safety, the incidence rates of the adverse reactions cardiotoxicity, leukopenia, thrombocytopenia, and gastrointestinal reactions were not significantly different between the two groups (OR = 1.70, 95% CI: 0.79–3.68; OR = 0.93, 95% CI: 0.61–1.42; OR = 1.08, 95% CI: 0.71–1.64; OR = 0.86, 95% CI: 0.56–1.30, respectively).ConclusionThe combined treatment had a better therapeutic effect than chemotherapy alone. It did not increase the incidence of adverse reactions in the course of treatment.
Highlights
This paper aims to compare the efficacy and safety of recombinant human endostatin combined with chemotherapy in patients with squamous cell lung cancer (SqCLC)
Inclusion and exclusion criteria The following were the inclusion criteria: (a) patients: they were diagnosed with SqCLC or Non-small cell lung cancer (NSCLC) and TNM stage III or IV; (b) interventions: the patients in the control group were given chemotherapy, while the patients in the experimental group were treated with Endostar on the basis of the control treatment; and (c) outcome indicators: the total effective rate, disease control rate, and drug-related adverse reactions were extracted from the studies
The quality assessment of studies A total of 14 articles were identified in the study, including six randomized controlled trials (RCTs) [12,13,14,15, 23, 24] and eight non-RCTs [16,17,18,19,20,21,22, 25], which were scored using corresponding quality assessment criteria
Summary
This paper aims to compare the efficacy and safety of recombinant human endostatin combined with chemotherapy in patients with squamous cell lung cancer (SqCLC). In 2018, there were an estimated 2.1 million new lung cancer cases and 1.8 million deaths worldwide, accounting for 11.6% and 18.4% of the cancer incidence and death, respectively. It is estimated that the number of patients diagnosed with lung cancer in the world within 5 years will be 2.13 million [2]. Non-small cell lung cancer (NSCLC) accounts for more than 80% of lung cancers. The preferred treatment of these cases is still based on chemotherapy and radiotherapy, but the overall prognosis is poor, so the treatment of SqCLC is urgent. Compared with other types of lung cancer, SqCLC is more closely related to smoking. Due to the low gene mutation rate, the effect of molecular targeted drug therapy is not significant at present [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
